Brought to you by 
Adaptive applies immunoSEQ to Janssen's drug candidates
10 Apr 2014
Executive Summary
Adaptive Biotechnologies Corp. (immunosequencing diagnostics) agreed to use its immunoSEQ immune profiling assay to characterize the immune response to diseases of interest for Johnson & Johnson’s Janssen R&D LLC. Adaptive will also apply the assay to certain immunology and oncology drugs Janssen is developing.
Deal Industry
- Pharmaceuticals
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Drug Discovery Tools
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adaptive applies immunoSEQ to Janssen's drug candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice